Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction

G. Barosi, A. Ambrosetti, A. Buratti, C. Finelli, N. L. Liberato, S. Quaglini, M. M. Ricetti, G. Visani, S. Tura, E. Ascari

Research output: Contribution to journalArticle

Abstract

Since according to the early studies, the outcome after splenectomy in the individual patient with myelofibrosis with myeloid metaplasia (MMM) is unpredictable, we assessed retrospectively the pre-intervention characteristics that best predicted adverse events, hematological consequences, and survival in 71 splenectomized MMM patients. The findings indicate that the operative risk of splenectomy for both mortality (8.4%) and morbidity (39.3%) was unpredictable. New hemorrhagic or thrombotic complications occurred in 16.9% of surviving patients and were predicted by age 200 × 109/l) and huge splenomegaly (>16 cm from the costal margin). Massive liver enlargement occurred in 24% of patients and has to be expected in patients splenectomized for transfusion-dependent anemia. Anemia improved substantially in 45% and 52% of patients at 3 months and at 1 year, respectively, and was predicted by severe anemia, low platelet count (9/l) or normal to high white blood cell (WBC) count (>4 × 109/l). Survival from splenectomy was superior in patients 9/l count. An unexpectedly high rate of blastic transformation was observed. It accounted for 42.8% of the deaths. The results suggest trials for prophylactic cytoreductive treatment in young patients and when platelet count is normal to increased. Further study is needed for elucidating the possible role played by splenectomy in inducing blastic transformation.

Original languageEnglish
Pages (from-to)200-206
Number of pages7
JournalLeukemia
Volume7
Issue number2
Publication statusPublished - Feb 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Fingerprint Dive into the research topics of 'Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction'. Together they form a unique fingerprint.

  • Cite this

    Barosi, G., Ambrosetti, A., Buratti, A., Finelli, C., Liberato, N. L., Quaglini, S., Ricetti, M. M., Visani, G., Tura, S., & Ascari, E. (1993). Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction. Leukemia, 7(2), 200-206.